pipeline
ANG-3777
Mechanism of Action
ANG-3777, is potentially a first-in-class hepatocyte growth factor (HGF) mimetic. We engineered ANG-3777 to mimic the biological activity of HGF in activating critical pathways in the body’s natural organ repair process following an acute organ injury.
Clinical Trials
Transplant-Associated Acute Kidney Injury (Delayed Graft Function): ANG-3777 is currently in a randomized, double-blind placebo-controlled Phase 3 trial for acute kidney injury associated with delayed graft function. Topline data are expected by mid-year 2021.
Acute Kidney Injury Associated with Cardiac Surgery Involving Cardiopulmonary Bypass (CSA-AKI): A randomized, double-blind, placebo-controlled Phase 2 trial examining the efficacy of ANG-3777 in reducing acute kidney injury in 240 patients after a cardiac procedure is currently enrolling. Topline phase 2 data are expected by year-end 2020.
ANG-3070
Mechanism of Action
ANG-3070, is a highly selective, orally-bioavailable small molecule tyrosine kinase receptor inhibitor developed internally as a potential treatment for fibrotic diseases, particularly in the lung and kidney.
Clinical Trials
Healthy Volunteer Study: ANG-3070 is currently in a Phase 1 healthy volunteer trial. We expect to complete this trial 2H-2020 and initiate a Phase 2 clinical trial in patients in 2021.
Preclinical Studies
• Lung Fibrosis
• Renal Disease and Fibrosis
ROCK2 INHIBITOR
Rho kinase (ROCK) signal transduction pathways are implicated in the development of fibrosis. Inhibition of the ROCK isoforms, ROCK1 and ROCK2, has shown promise in fibrosis; however, ROCK1 inhibition has been associated with inducing hypotension. Recent scientific work using specific genetic or pharmacological inhibition of ROCK2 indicates ROCK2 inhibition alone can result in anti-fibrotic activity without causing hypotension. These findings informed our strategy to develop ROCK2-specific inhibitors as a potential treatment of fibrosis.
Dual ROCK1/2 inhibitors have been shown to have problematic side effects including hypotension and vascular permeability. However, in vivo studies demonstrate our lead compound has more than five hundred-fold selectivity for ROCK2 versus ROCK1. We believe high selectivity for ROCK2 could translate into a product candidate with enhanced tolerability that may support long-term systemic use.
The initial focus for our ROCK2 program is expected to be on fibrotic indications such as chronic kidney disease, IPF and nonalcoholic steatohepatitis (NASH). Given the heterogeneity of these diseases, we believe development of this program will benefit from our precision medicine approach and use of established clinical biomarkers.
